The IDO (indoleamine 2,3-dioxygenase 1, IDO1, IDO-1, INDO, indoleamine-pyrrole 2,3-dioxygenase) inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global IDO inhibitors market. Most of the pipeline therapeutics are in early stage of development, the market is yet to witness first IDO inhibitor launch and its impact on overall oncology market.
A few large pharmaceutical companies are investing billions of dollars through multiple collaboration agreements for the R&D for IDO inhibitors. The synergistic effects of IDO inhibitors with chemotherapy together may create a new opportunity for vaccines and immunotherapy. The combination of IDO inhibitors with vaccines can redefine the cancer treatment in coming years if everything goes in the right direction as per the initial results.
Covered in this report
The report covers the present scenario and the growth prospects of the IDO inhibitors. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
Technavio's IDO Inhibitors - A Pipeline Analysis Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects during the forecast period. The report also includes a discussion of the key companies operating in this market.
- Bristol-Myers Squibb
- Kyowa Hakko Kirin
- How will the market evolve during the forecast period?
- What are the major parameters impacting the market?
- What are the key market trends?
- What are the challenges to market growth?
- Who are the key companies in this market space?
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: IDO INHIBITORS: AN INSIGHT
PART 07: COMPARATIVE ANALYSIS
- Late-stage molecule (Phase III)
- Mid-stage molecule (Phase II)
- Early-stage molecules (Phase I/II and I)
- Pre-clinical and discovery stage molecules
- Inactive molecules
PART 09: THERAPEUTIC ASSESSMENT BY THERAPY
- Therapeutic assessment based on therapy
- Therapeutic assessment based on RoA
- Therapeutic assessment based on molecule type
- Active companies: Category and parameters
- List of abbreviations
Exhibit 01: Overview of collaboration agreements in global IDO inhibitors market 2017
Exhibit 02: Drug approval process by US FDA
Exhibit 03: Pipeline landscape
Exhibit 04: Pipeline molecules by vendors
Exhibit 05: Pipeline molecules by numbers
Exhibit 06: Pipeline molecules by percentage
Exhibit 07: Overview: Epacadostat
Exhibit 08: Clinical trials description of epacadostat
Exhibit 09: Overview: Indoximod
Exhibit 10: Clinical trials description of indoximod
Exhibit 11: Overview: BMS-986205
Exhibit 12: Clinical trials description of BMS-986205
Exhibit 13: Overview: Navoximod
Exhibit 14: Clinical trials description of navoximod
Exhibit 15: Overview: PF 06840003
Exhibit 16: Clinical trials description of PF-06840003
Exhibit 17: Overview: KHK2455 oral
Exhibit 18: Clinical trials description of KHK2455 oral
Exhibit 19: Overview: NLG802
Exhibit 20: Clinical trials description of NLG802
Exhibit 21: Overview: IDO inhibitor
Exhibit 22: Overview: GBV1012
Exhibit 23: Overview: GBV1028
Exhibit 24: Overview: RG70099
Exhibit 25: Overview: IDO inhibitor
Exhibit 26: Overview: IDO1 inhibitor
Exhibit 27: Overview: Dual IDO1/TDO inhibitor
Exhibit 28: Overview: IDO-1 inhibitor
Exhibit 29: Overview: dCellVax
Exhibit 30: Overview: IDO1 Inhibitor
Exhibit 31: Overview: Covalent IDO inhibitors
Exhibit 32: Dormant Products,2017
Exhibit 33: Analysis by indication
Exhibit 34: An overview of top five indications (courtesy
Exhibit 35: Assessment of pipeline products by therapy
Exhibit 36: Assessment by RoA
Exhibit 37: Assessment by molecule type
Exhibit 38: Assessment of molecule types in various stages
Exhibit 39: Active companies: Category and parameters 2017
Exhibit 40: Segmentation of companies
Exhibit 41: Overview: Aurigene Discovery Technologies 2017
Exhibit 42: Overview: Bristol-Myers Squibb 2017
Exhibit 43: Overview: Curadev Pharma 2017
Exhibit 44: Overview: Globavir Biosciences 2017
Exhibit 45: Overview: Incyte Corporation 2017
Exhibit 46: Overview: IOmet Pharma 2017
*Financials are for parent company
Exhibit 47: Overview: Kyowa Hakko Kirin 2016
Exhibit 48: Overview: Netherlands Translational Research Center (NTRC) 2017
Exhibit 49: Overview: NewLink Genetics Corporation 2017
Exhibit 50: Overview: Pfizer 2017
Exhibit 51: Overview: Redx Pharma 2017
Exhibit 52: Overview: Ensemble Therapeutics 2017
Exhibit 53: Overview: Regen BioPharma 2017
The author of the report recognizes the following companies in the IDO inhibitors: Pfizer, Bristol-Myers Squibb, and Kyowa Hakko Kirin.
Indoleamine-2,3-dioxygenase (IDO) is one of the several immune checkpoints involved in tumor immune escape. It is an intracellular heme-containing enzyme that initiates the first and rate-limiting step of tryptophan degradation along with the kynurenine pathway. By inhibiting IDO, researchers hope to restore immune system responses so that cancer cells can be more easily identified and destroyed.
As most of the IDO inhibitors are currently in the very nascent stage, predicting the future is not sensible at this point of time. However, if it succeeds to enter the market in coming years, then IDO inhibitors may not only transform the way to treat advanced melanoma, but also how the treatment for non-small lung cancer, triple-negative breast cancer, and bladder cancer are being carried out with the existing therapies. Most likely that would be huge news for the researchers and the patients as well.
The global IDO inhibitors market is still to witness its first approval for the various type of solid tumors. The majority of the pipeline molecules are still in pre-clinical stage, a few being in Phase II, and only one candidate made its way to Phase III stage of development so far.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.